Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

[1]  N. Raine-Fenning,et al.  Results of randomised trial , 2019 .

[2]  T. Bosse,et al.  Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial. , 2018, Gynecologic oncology.

[3]  H. Putter,et al.  Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  H. Morreau,et al.  Practical guidance for mismatch repair-deficiency testing in endometrial cancer. , 2017 .

[5]  K. K. van de Vijver,et al.  L1CAM expression in endometrial carcinomas: an ENITEC collaboration study , 2016, British Journal of Cancer.

[6]  H. Putter,et al.  Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts , 2016, Clinical Cancer Research.

[7]  E. Darai,et al.  Endometrial cancer , 2016, The Lancet.

[8]  H. Mackay,et al.  Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer , 2016, Modern Pathology.

[9]  H. Putter,et al.  Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial. , 2015, International journal of radiation oncology, biology, physics.

[10]  T. Bosse,et al.  Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials. , 2015, European journal of cancer.

[11]  A. Talhouk,et al.  A clinically applicable molecular-based classification for endometrial cancers , 2015, British Journal of Cancer.

[12]  D. Lambrechts,et al.  Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer , 2014, Journal of the National Cancer Institute.

[13]  T. Bosse,et al.  L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. , 2014, European journal of cancer.

[14]  P. Altevogt,et al.  L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. , 2013, Journal of the National Cancer Institute.

[15]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[16]  H. Putter,et al.  Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. , 2012, European journal of cancer.

[17]  H. Andersson,et al.  External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma--a prospective randomized study. , 2012, International journal of radiation oncology, biology, physics.

[18]  Rémi,et al.  Endometrium FIFTEEN-YEAR RADIOTHERAPY OUTCOMES OF THE RANDOMIZED PORTEC-1 TRIAL FOR ENDOMETRIAL CARCINOMA , 2011 .

[19]  Cyrus Chargari,et al.  Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients. , 2011, International journal of radiation oncology, biology, physics.

[20]  G. Thomas.  A Role for Adjuvant Radiation in Clinically Early Carcinoma of the Endometrium? , 2010, International Journal of Gynecologic Cancer.

[21]  R. Berkowitz,et al.  Faculty Opinions recommendation of Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. , 2010 .

[22]  H. Putter,et al.  Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial , 2010, The Lancet.

[23]  S. Stamm,et al.  Alternative Splicing-Related Factor YT521: an Independent Prognostic Factor in Endometrial Cancer , 2010, International Journal of Gynecologic Cancer.

[24]  Hein Putter,et al.  Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  V. Torri,et al.  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. , 2009, Journal of the National Cancer Institute.

[26]  M. Parmar,et al.  Lymphadenectomy in endometrial cancer – Authors' reply , 2009, The Lancet.

[27]  T. Whelan,et al.  Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis , 2009, The Lancet.

[28]  M. Parmar,et al.  Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study , 2009, The Lancet.

[29]  Jamie Weydert,et al.  Mandatory Second Opinion in Surgical Pathology Referral Material: Clinical Consequences of Major Disagreements , 2008, The American journal of surgical pathology.

[30]  H. Putter,et al.  5000 ORAL Quality of life after radiotherapy for endometrial cancer: first results from the randomized PORTEC-2 trial , 2007 .

[31]  P. Zola,et al.  Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial , 2006, British Journal of Cancer.

[32]  H. Boezen,et al.  Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. , 2005, Gynecologic oncology.

[33]  M. Maiman,et al.  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study , 2004 .

[34]  W. van Putten,et al.  Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma , 2004, Cancer.

[35]  D. Mutch,et al.  Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer , 2002 .

[36]  E. Noordijk,et al.  Long-term outcome in endometrial carcinoma favors a two- instead of a three-tiered grading system. , 2002, International journal of radiation oncology, biology, physics.

[37]  P. Koper,et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. , 2000 .

[38]  P. Koper,et al.  Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial , 2000, The Lancet.

[39]  M. Wood,et al.  Analysis and interpretation of data. , 1978, The Journal of family practice.

[40]  L. V. van de Poll-Franse,et al.  Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Nobuyuki Susumu,et al.  Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[42]  Patrick Neven,et al.  Endometrial cancer. , 2005, Lancet.

[43]  A. Jaffe,et al.  Reduction of infarct size in patients with inferior infarction with intravenous glyceryl trinitrate. A randomised study. , 1983, British heart journal.

[44]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.